Clearmind Files Hong Kong Patent for Non-Hallucinogenic Depression Therapy
Event summary
- Clearmind Medicine filed a patent application in Hong Kong for a novel depression therapy combining MEAI and PEA.
- The treatment targets major depressive disorder (MDD), affecting over 332 million people globally.
- The therapy is designed as a non-hallucinogenic alternative to existing antidepressants like SSRIs.
- Clearmind partners with NeuroThera Labs, a subsidiary of SciSparc, for PEA sourcing.
The big picture
Clearmind’s Hong Kong patent filing underscores the growing interest in non-hallucinogenic psychedelic-derived therapies for mental health. The global depression treatment market is surging, with demand for safer, more accessible alternatives to traditional antidepressants. This strategic move positions Clearmind at the forefront of neuroplastogen innovation, leveraging partnerships to strengthen its intellectual property and commercialization efforts.
What we're watching
- Regulatory Approval
- Whether Clearmind can secure regulatory approval for its non-hallucinogenic therapy in key markets.
- Market Penetration
- The pace at which the company can capture share in the $25B+ depression treatment market by 2030.
- Intellectual Property
- How Clearmind’s expanding patent portfolio will influence its competitive positioning.
Related topics